文献清单： “纳米药物载体”方向 MDPI Pharmaceutics。期刊名：Pharmaceutics
期刊主页：https://www.mdpi.com/journal/pharmaceutics
1. Recent Advances in Photodynamic Therapy: Metal-Based Nanoparticles as Tools to Improve Cancer Therapy
光动力疗法的最新进展：金属纳米粒子作为改善癌症治疗的工具
文章链接：https://www.mdpi.com/1999-4923/16/7/932
2.Development and Evaluation of Docetaxel-Loaded Nanostructured Lipid Carriers for Skin Cancer Therapy
用于皮肤癌治疗的多西他赛纳米结构脂质载体的开发与评价
文章链接： https://www.mdpi.com/1999-4923/16/7/960
3.Recent Trends in Curcumin-Containing Inorganic-Based Nanoparticles Intended for In Vivo Cancer Therapy
用于体内癌症治疗的含姜黄素无机纳米颗粒的最新研究进展
文章链接：https://www.mdpi.com/1999-4923/16/2/177
4.Advances in Nanoparticles as Non-Viral Vectors for Efficient Delivery of CRISPR/Cas9
纳米颗粒作为非病毒载体在高效递送 CRISPR/Cas9 方面的进展
文章链接：https://www.mdpi.com/1999-4923/16/9/1197
5.Effect of Lipid Nanoparticle Physico-Chemical Properties and Composition on Their Interaction with the Immune System
脂质纳米颗粒的理化性质和组成对其与免疫系统相互作用的影响
文章链接：https://www.mdpi.com/1999-4923/16/12/1521
6.Ivermectin-Loaded Mesoporous Silica and Polymeric Nanocapsules: Impact on Drug Loading, In Vitro Solubility Enhancement, and Release Performance
伊维菌素负载介孔二氧化硅和聚合物纳米胶囊：对载药量、体外溶解度增强和释放性能的影响
文章链接：http://www.mdpi.com/1999-4923/16/3/325
7.Cationic Hydroxyethyl Cellulose Nanocomplexes and RANK siRNA/Zoledronate Co-Delivery Systems for Osteoclast Inhibition
阳离子羟乙基纤维素纳米复合物和RANK siRNA/唑来膦酸共递送系统用于抑制破骨细胞
文章链接：http://www.mdpi.com/1999-4923/16/3/396
8.Innovative Delivery Systems for Curcumin: Exploring Nanosized and Conventional Formulations
姜黄素的创新递送系统：探索纳米级和传统制剂
文章链接： https://www.mdpi.com/1999-4923/16/5/637
9.An Efficient Fabrication Approach for Multi-Cancer Responsive Chemoimmuno Co-Delivery Nanoparticles
一种高效的多癌响应性化疗免疫共递送纳米粒子的制备方法
文章链接： https://www.mdpi.com/1999-4923/16/10/1246
10. Future-Oriented Nanosystems Composed of Polyamidoamine Dendrimer and Biodegradable Polymers as an Anticancer Drug Carrier for Potential Targeted Treatment
由聚酰胺胺树状聚合物和生物可降解聚合物组成的面向未来的纳米系统，可作为抗癌药物载体用于潜在的靶向治疗
文章链接：https://www.mdpi.com/1999-4923/16/11/1482
来源：Pharmaceutics
